How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors



Cybulska, Barbara, Klosiewicz-Latoszek, Longina, Penson, Peter E ORCID: 0000-0001-6763-1489, Nabavi, Seyed Mohammad, Lavie, Carl J, Banach, Maciej and ILEP, Int Lipid Expert Panel
(2021) How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. PROGRESS IN CARDIOVASCULAR DISEASES, 67. 65 - 74.

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Uncontrolled Keywords: High risk patients, Lipids, LDL cholesterol, PCSK9 inihbitors, Safety, Statins
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 01 Jul 2021 07:30
Last Modified: 24 Aug 2022 17:12
DOI: 10.1016/j.pcad.2020.12.008
Open Access URL: http://researchonline.ljmu.ac.uk/id/eprint/14560/
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3128375